
BlueLight Therapeutics develops novel therapeutic molecules for challenging drug targets using a proprietary platform.
Founded with a mission to address challenging drug targets, BlueLight Therapeutics leverages a proprietary structure-based platform to discover and develop novel small molecules. The company focuses on creating therapeutic solutions for difficult-to-drug targets, aiming to bring innovative treatments to market. Their expertise spans across a broad range of target classes, driven by a passionate and experienced team dedicated to advancing the field of drug discovery.
Notable figures affiliated with BlueLight Therapeutics include experts in structural assays and drug development, though specific names are not provided. The company has made significant strides in the biotech industry, marked by its unique approach and proprietary technology. BlueLight Therapeutics' impact is reflected in its potential to transform therapeutic strategies for high-value, complex drug targets, contributing to advancements in medical treatments and patient care.

MapLight Therapeutics

Ventus Therapeutics

Ensem Therapeutics
ensemtx.com

Bluejay Therapeutics
bluejaytx.com

Exo Therapeutics

Septerna
septerna.com

Jnana Therapeutics
jnanatx.com

Blade Therapeutics

Deep Apple Therapeutics
deepappletx.com

ZielBio
zielbio.com

Blue Oak Pharmaceuticals
blueoakpharma.com

Belharra Therapeutics

Blue Note Therapeutics

ProFound Therapeutics
profoundtx.com

BridGene Biosciences
Companies similar to BlueLight Therapeutics include MapLight Therapeutics, Ventus Therapeutics, Ensem Therapeutics and Bluejay Therapeutics.
BlueLight Therapeutics was founded in 2000.
BlueLight Therapeutics' headquarters is located in Burlingame, CA, US.
BlueLight Therapeutics' most recent funding round was for $20M (USD) in September 2018.
As of Sep 10, 2018, BlueLight Therapeutics has raised a total of $46.6M (USD).
BlueLight Therapeutics has 30 employees as of Feb 4, 2024.